Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease

Medicine (United States)

Volumn 97, Issue 11, 2018, Pages

  Jung, Hye In ^a   Park, Jae Seok ^a   Lee, Mi Young ^b   Park, Byeongju ^c   Kim, Hyun Jung ^a   Park, Sun Hyo ^a   Choi, Won Il ^b   Lee, Choong Won ^d  

^a Department of Internal Medicine ^*  (China)

^b Keimyung University   (South Korea)

^c Kyungpook National University   (South Korea)

^d Sungso Hospital   (South Korea)

Author keywords

interstitial lung disease; lung cancer; prevalence

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FIBROSING ALVEOLITIS; GENDER; HUMAN; ICD-10; INTERSTITIAL LUNG DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; X-RAY COMPUTED TOMOGRAPHY;

ADULT; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85044038858     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000010071     Document Type: Article

References (39)

1. Liebow A. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 1975;8:1.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
3. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
4. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 2011;37:743-6.
5. Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc 2014;11:1176-85.
6. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72.
7. Gjonbrataj J, ChoiWI, Bahn YE, et al. Incidence of idiopathic pulmonary fibrosis in Korea based on the 2011 ATS/ERS/JRS/ALAT statement. Int J Tuberc Lung Dis 2015;19:742-6.
8. Grimminger F, Gunther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 2015;45: 1426-33.
9. Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011;208:1459-71.
10. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999;149:13-20.
11. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-25.
12. de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease-incidence and predicting factors. Am J Respir Crit Care Med 2011;184:913-9.
13. Riffenburgh RH. Statistics in Medicine. 3rd ed. London: Academic Press, 2012.
14. Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: Analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J 1996;89:505-10.
15. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995;45:925-32.
16. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000;161:5-8.
17. Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Vol 101. Respir Med 2007;2534-40.
18. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001;17:1216-9.
19. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364:1503-12.
20. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41.
21. Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980;35:496-9.
22. Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: A population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7.
23. Lee SJ, Kim SW, Kong KA, et al. Risk factors for chronic obstructive pulmonary disease among never-smokers in Korea. Int J Chron Obstruct Pulmon Dis 2015;10:497-506.
24. Lee SH, Kim DS, Kim YW, et al. Association between occupational dust exposure and prognosis of idiopathic pulmonary fibrosis: A Korean national survey. Chest 2015;147:465-74.
25. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007;175:705-11.
26. Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987;106:512-8.
27. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986;105:503-7.
28. Kang KY, Yim HW, Kim IJ, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009;38:299-303.
29. Hill CL, Nguyen AM, Roder D, et al. Risk of cancer in patients with scleroderma: A population based cohort study. Ann Rheum Dis 2003;62:728-31.
30. Chatterjee S, Dombi GW, Severson RK, et al. Risk of malignancy in scleroderma: A population-based cohort study. Arthritis Rheum 2005;52:2415-24.
31. Huang YL, Chen YJ, Lin MW, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: A nationwide populationbased study. Br J Dermatol 2009;161:854-60.
32. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 2001;357:96-100.
33. Antiochos BB, Brown LA, Li Z, et al. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 2009;36:2704-10.
34. Yamada T, Nakajima A, Inoue E, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 2011;31: 1487-92.
35. Parikh-Patel A, White RH, Allen M, et al. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009;20:1001-10.
36. Khurana R, Wolf R, Berney S, et al. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: A large case control study in US veterans. J Rheumatol 2008;35:1704-8.
37. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol 2009;23:539-47.
38. Bernatsky S, Boivin JF, Joseph L, et al. Aninternational cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90.
39. Ragnarsson O, Grondal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 2003;12:687-91.